Effectiveness of platelet rich plasma in comparison with Triamcinolone Hexacetonide in improving pain and function in patients with de Quervains tenosynovitis: A Randomised controlled trial - Nil

开始日期2024-08-20

申办/合作机构

Regional Institute of Medical Sciences

CTRI/2024/06/069688

/ Not yet recruiting临床4期

A Prospective, Multicenter, Open-label, Post-Marketing Observational Study to Evaluate the Effectiveness and Safety of Triamcinolone Hexacetonide Intra-Articular Injection in Adhesive Capsulitis of the Shoulder (Frozen Shoulder) - NIL

开始日期2024-07-09

申办/合作机构

Abbott India Ltd.

NCT06308887

/ Completed临床4期IIT

Comparison of the Effectiveness of Ultrasound-Guided Perimeniscal Steroid and Dextrose Injections in Knee Osteoarthritis

Introduction: The primary goal of treating knee osteoarthritis is to reduce pain and improve the patient's quality of life. Medial meniscal extrusion is a condition that is linked to pain and disability in knee osteoarthritis and can be identified through ultrasound. For patients with medial meniscal extrusion, perimeniscal corticosteroid injection has been shown to be a helpful addition to primary treatment for moderate to severe pain relief. Dextrose prolotherapy has also been found to provide periarticular benefits for knee osteoarthritis. This study aims to compare the effectiveness of ultrasound-guided perimeniscal corticosteroid and perimeniscal dextrose injections in patients with osteoarthritis, medial knee pain, and medial meniscal extrusion.
Method: Patients with medial knee pain and meniscal extrusion were randomly divided into two groups using the double-block randomization method. Group 1 included 15 patients who were administered an ultrasound-guided perimeniscal steroid injection, while Group 2 included 16 patients who were administered an ultrasound-guided perimeniscal dextrose injection. The patients' pain levels were evaluated using the Visual Analog Pain Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) before and one week, one month, and three months after the injection.

开始日期2023-10-02

申办/合作机构

Kastamonu University

100 项与己曲安奈德相关的临床结果

登录后查看更多信息

100 项与己曲安奈德相关的转化医学

登录后查看更多信息

100 项与己曲安奈德相关的专利（医药）

登录后查看更多信息

304

项与己曲安奈德相关的文献（医药）

2025-04-01·Orthopaedics & Traumatology-Surgery & Research

Survivorship and outcomes of intra- and perimeniscal corticosteroids injections with structured physiotherapy for degenerative medial meniscus tears

Article

作者: Jacquet, Christophe ; Mabrouk, Ahmed ; Guenoun, Daphne ; Ollivier, Matthieu ; Onishi, Shintaro ; Cavaignac, Etienne

BACKGROUND:

Degenerative medial meniscus tears are a common pathology in the general population. Recent randomized trials demonstrated non-superiority of arthroscopic partial meniscectomy over conservative management. However, there is a paucity of information regarding the outcomes of combined conservative treatments.

HYPOTHESIS:

It was hypothesized that combined intra- and perimeniscal corticosteroid injections with structured physiotherapy, for degenerative medial meniscus tears, would result in high surgery-free and second injection-free survivorship.

METHODS:

A retrospective review of 671 patients with symptomatic degenerative medial meniscus tears, who received intra- and perimeniscal corticosteroids injection combined with structured physiotherapy, was conducted. An ultrasound-guided injection of Triamcinolone Hexacetonide 20 mg/ml comprised; 1.5 ml intra-meniscal,1.5 ml in the meniscal wall, and 2 ml in the peri-meniscal space, was performed. Surgery free- and a second injection free-survivorship were analysed. Western Ontario and Macmaster University scores (WOMAC), Tegner activity scores, patient satisfaction, return-to-work status and average time to return to work were recorded.

RESULTS:

A total of 481 patients who met the inclusion criteria were included. The mean age was 51.1 ± 7.9 years. At five years post-procedure, surgery-free, and second injection-free survivorship of the ipsilateral knee was 83%, and 52%, respectively. A multivariate analysis adjusting survival on parametric risk factors identified that only effusion before steroid injection was an independent risk factor of treatment failure. At a mean follow-up of 4 ± 2 years, there was an improvement in WOMAC scores by 5.2 ± 4.9 for pain, by 2 ± 2 for stiffness, by 7.3 ± 7.4 for function, and by 12.4 ± 12.7 for the global scores. Additionally, there was significant improvement in the Tegner activity scores (All p < 0.001). Knee effusion and advanced osteoarthritis (Kellgren-Lawrence > III) were significantly associated with poorer outcomes; p < 0.003 and p < 0.0004, respectively.

CONCLUSION:

A combination of intra- and perimeniscal corticosteroid injections and structured physiotherapy for degenerative medial meniscus tears, results in high surgery-free (83%) and second injection-free (52%) survivorship, as well as, effective clinical outcomes and satisfaction at 5 years.

LEVEL OF EVIDENCE:

IV; Retrospective Case Series.

2025-02-01·Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine

Intra-articular injection of a cross-linked hyaluronic acid combined with triamcinolone hexacetonide improves pain at six months in patients with mild to moderate hip osteoarthritis: A prospective observational study

Article

作者: Dessouki, Shariff ; Williams, Ryan ; Lautenbach, Justin ; Rabinovich, Alexander ; Duong, Andrew ; Dalziel, Katie ; Hitchon, Maggie ; Maida, Eugene ; Kapuvari, Stephen ; de SA, Darren ; Bourgeault-Gagnon, Yoan ; Ayeni, Olufemi R. ; Heels-Ansdell, Diane ; Simunovic, Nicole ; Sim, Yan

OBJECTIVES:

Joint-preserving interventions, such as intra-articular viscosupplementation injections, are evolving and requiring efficacy and safety evaluations through an evidence-based approach. The objective of this study was to assess the use of a hyaluronic acid and corticosteroid-based injection (Cingal™; Anika Therapeutics, Bedford, MA, USA) in improving pain and functional outcomes for patients aged between 40 and 65 with mild to moderate hip osteoarthritis (OA) six months post-injection.

METHODS:

This prospective observational study included 100 patients receiving a single ultrasound-guided intra-articular injection of Cingal™. Eligible patients seen in participating orthopaedic, physiatry and sports medicine clinics were evaluated at baseline, one-month, and six-month follow-up. The primary outcome was patient-reported hip pain (Visual Analogue Scale, VAS) at six months post-injection. Secondary outcomes included hip function (Hip Disability and Osteoarthritis Outcome Score, HOOS), quality of life (Short-Form 12, SF-12), pain medication use, range of motion (ROM), physical activity (activity tracker), and adverse events.

RESULTS:

Ninety-six patients received the injection; 91 had complete data for primary outcome analysis. Statistically significant improvements were observed in VAS (p < 0.001), HOOS (p < 0.001), and SF-12 scores (Physical Component Summary, p = 0.005; Mental Component Summary, p = 0.022) from baseline to six months post-injection. Pain medication use decreased from 50.0% to 34.0% (p = 0.035). No statistically significant change was observed in ROM or activity level. Adverse events were reported in 9.5% of patients: five (5.3%) experienced hip pain for less than seven days, one for more than seven days but less than one month, and three (3.2%) underwent hip arthroplasty.

CONCLUSION:

Patients receiving an ultrasound-guided Cingal™ injection for hip OA reported statistically significantly reduced hip pain, improved function and quality of life, and reduced pain medication use at six months. The most common adverse event was transient hip pain.

LEVEL OF EVIDENCE:

Prospective observational study, Level III.

2024-11-16·POSTGRADUATE MEDICINE

Juvenile idiopathic arthritis management: insights into the utilization of intra-articular corticosteroid injections

Article

作者: Yildirim, Deniz Gezgin ; Bakkaloğlu, Sevcan A. ; Yıldız, Çisem ; Esmeray Şenol, Pelin ; Küçükali, Batuhan ; Kutlar, Merve ; Sunar Yayla, Emine Nur ; Karaçayır, Nihal ; Belder, Nuran

BACKGROUND:

Juvenile idiopathic arthritis (JIA) is a common chronic rheumatic disease in children, requiring careful management to reduce both short- and long-term morbidity. In this study, our objective was to assess the clinical features of patients diagnosed with JIA who received intra-articular corticosteroid injections (IACI).

METHODS:

In this retrospective study, we evaluated the clinical and laboratory characteristics of 225 JIA patients monitored from January 2012 to October 2023 at a tertiary care center. We focused on patients who underwent intra-articular corticosteroid injections (IACI) as part of their treatment. Triamcinolone hexacetonide (TH) was used due to its demonstrated safety and efficacy.

RESULTS:

Our analysis revealed that IACI, particularly utilizing TH, was a widely employed and effective adjunct therapy, contributing to rapid symptom relief and local disease control. Patients receiving IACI exhibited earlier symptom onset, younger age at diagnosis, longer follow-up durations, and higher cumulative treatment burden (p < 0.001, p < 0.001, p < 0.01, p < 0.001 respectively). Despite inconclusive acute-phase reactants, a higher frequency of ANA positivity and elevated initial lymphocyte counts were associated with increased IACI use (p < 0.001, p < 0.001 respectively). Importantly, on a joint basis, a high percentage of arthritis remission following IACI underscores its efficacy and favorable safety profile.

CONCLUSIONS:

Notably, the high percentage of arthritis remission achieved with intra-articular corticosteroid injections (IACI) on a joint-specific basis highlights its efficacy and favorable safety profile. A lymphocyte count exceeding 5000/mm³ at the time of diagnosis may serve as an early indicator for considering intra-articular steroid administration. These findings emphasize the need for nuanced and individualized treatment strategies in JIA management to optimize outcomes for affected children.

项与己曲安奈德相关的新闻（医药）

2026-01-15

·知乎专栏

糖皮质激素（GCs）与受体GR：作用机制、分类框架与最新进展（附产品选型表）

糖皮质激素是什么？糖皮质激素（glucocorticoids, GCs）是一类由肾上腺皮质以胆固醇为前体合成的甾体激素，主要在皮质束状带生成；在人类以内源性皮质醇（cortisol）为主（皮质酮通常更低；而大鼠/小鼠以皮质酮为主）。容易混淆的点：“皮质激素（corticosteroids）”是更大的总称，通常包括1. 糖皮质激素（GCs）：偏代谢调控 + 抗炎/免疫调节 + 应激适应2. 盐皮质激素（mineralocorticoids, 如醛固酮）：偏电解质/体液容量与血压（主要受 RAAS 与血钾调控，ACTH 可提供短期刺激，但长期主控仍是 RAAS/血钾。）糖皮质激素有哪些“典型特征”？把它想成“能穿膜的化学信号”，糖皮质激素（GCs, glucocorticoids）的典型特征可用四句话概括：1.脂溶性：游离态 GCs 可跨膜进入细胞，结合糖皮质激素受体（GR, glucocorticoid receptor），经典效应多通过调控基因表达实现（也可有部分快速非基因组效应）。2.作用广但“因地制宜”：多数组织具备响应能力，参与代谢稳态、应激适应与炎症/免疫调节，但效应强弱高度依赖组织/细胞背景与共调控网络。3.节律 + 负反馈：下丘脑–垂体–肾上腺轴（HPA axis, hypothalamic–pituitary–adrenal axis）驱动昼夜节律并在应激时升高，同时通过负反馈抑制上游信号以防失控。皮质醇也有超日节律/脉冲（ultradian pulses）。4.临床价值高但“用量决定代价”：抗炎/免疫抑制效应强，因此治疗价值大；但全身用药的不良反应与剂量/疗程（以及给药途径）强相关，常见风险包括代谢异常、骨质疏松/骨折、感染风险上升与 HPA 轴抑制等。它们在哪些领域起作用？分别“在做什么事”？A. 生理学：身体为什么需要它？1.应激与能量调度：糖皮质激素（GCs, glucocorticoids）在感染/炎症/饥饿/压力等情况下，帮助维持葡萄糖供应与能量动员，并对血管反应性与循环稳态具有“许可/维持”作用。2.免疫与炎症“刹车”：通过糖皮质激素受体（GR, glucocorticoid receptor）重排炎症基因网络（如抑制 NF-κB、AP-1 等通路），把免疫反应从“失控放大”拉回“可控范围”，并促进炎症分辨。3.日常稳态：GCs 也参与昼夜节律下的稳态维护，不只是“应激时才上场”。 B. 医学与药学：为什么它是“超级常用药”？合成糖皮质激素在多个学科高频使用（过敏/哮喘、风湿免疫、皮肤、移植、血液肿瘤方案支持、危重症等），核心原因是其可通过GR 介导的转录调控强力压制炎症程序；同时给药路径多（局部与全身均可），便于在不少场景实现“靶器官获益更大、全身副作用尽量更小”。糖皮质激素受体GR（glucocorticoid receptor）是什么？ GR 是糖皮质激素作用的主要受体：一种细胞内、配体依赖的转录调控因子，属于核受体（nuclear receptor）超家族；人类基因为 NR3C1（nuclear receptor subfamily 3 group C member 1）。GR 怎么工作？（从细胞质到细胞核的“4 步动作”）1.未结合激素时：GR 多位于细胞质，与伴侣蛋白复合物（Hsp90/Hsp70，heat shock proteins；以及 FKBP51/52，FK506 binding proteins 等）结合并处于可激活状态（也可一定程度穿梭于核/胞质）。2.激素进入细胞并结合 GR：诱导构象变化并触发伴侣蛋白重排。3.GR 转位入核：GR 转位入核后可直接结合 GRE（glucocorticoid response element），或以“系链（tethering）”方式调控 NF-κB、AP-1 等转录因子网络。4.改变基因表达网络：既能上调也能下调，效果强烈依赖细胞类型与染色质环境。结构上，GR 典型由 N 端转录激活区（NTD/AF-1）、DNA 结合域（DBD，含锌指）、铰链区与配体结合域（LBD/AF-2）构成。可以形象理解成：激素是钥匙，GR 是锁；但这把锁一旦被打开，会去“改写一大批基因的开关状态”。备注：伴侣蛋白（molecular chaperones）：帮助受体蛋白维持正确构象并完成装配/运输的“蛋白质助手”；FKBP51/52 属于共伴侣（co-chaperones）。GR 重要吗？重要，是很多疾病与药物效应的“总阀门”原因主要有三条：1.几乎所有治疗性糖皮质激素的效果，最终都要通过 GR（及其网络）落地。2.同样剂量有人很有效/有人副作用大，与 GR 相关机制（受体异构体、伴侣蛋白、代谢酶、共调节因子等）有关；但现实中我们缺少可靠的“用药前预测指标”。 3.“激素抵抗（glucocorticoid resistance）”是临床与研究的大问题（如部分哮喘、炎症性疾病、某些肿瘤/免疫状态），常涉及 GR 信号层层环节。如何对 GR“分类”？分类轴子类/选项一句话定义关键细节/常见误区1 按“受体本体”分（isoforms/异构体）GRα（glucocorticoid receptor alpha）经典主力形式：能结合糖皮质激素并介导大多数经典效应不止一种蛋白形态：同属 GRα，仍可因不同翻译起始位点产生多种 N 端长度不同的亚型（文献常用 GR-A/B/C/D 指代），活性谱/基因选择性可不同；因此“同为 GRα”也能出现组织差异GRβ（glucocorticoid receptor beta）由可变剪接产生；通常认为不结合常规糖皮质激素，并可在部分情境下对 GRα 起负向调节/主导负性（dominant-negative）作用误区：把 GRβ 只当“刹车”。GRβ 在一些模型中可能还具有GRα 之外的独立功能（与细胞背景强相关）其他 GR 异构体除 α/β 外，NR3C1 还可产生其他剪接/起始位点组合（综述中常见如 GRγ、GR-P 等命名）“GR 不止 α/β”2 按“信号输出方式”分（signaling modes/信号模式）基因组作用（genomic actions，基因组途径）GR 入核后调控转录，是最系统、最核心的作用方式3 种典型“核内落地方式”：①直绑 GRE（glucocorticoid response element，糖皮质激素反应元件）；②tethering（系链）到炎症转录因子如 NF-κB（nuclear factor kappa B）、AP-1（activator protein-1）；③通过负向调控元件（如 nGRE, negative GRE）等实现下调非基因组作用（non-genomic actions，非基因组途径）更快（秒–分钟级）的效应，可通过膜/胞质层面的相互作用影响信号通路非基因组效应在多种情境都可能出现，机制可涉及膜起始信号、离子通道/激酶级联、以及经典受体参与的快速过程3 按“药理学调节方式”分（pharmacological modulation/药理调节）激动剂（agonists，激动剂；多数临床用药）激活 GR，重塑炎症/免疫与代谢相关网络（疗效强）关键现实点：作用面广 → 副作用也来自‘太广’；并且“全身 vs 局部给药”（吸入/外用/关节腔等）会显著改变风险–收益拮抗剂/阻断剂（antagonists，拮抗剂）阻断 GR 信号，用于需要降低皮质醇效应的特定情境（如库欣综合征相关策略）属于更专门的路径，临床适应证与监测要求更严格选择性 GR 调节剂（SEGRMs/SEGRAs：selective glucocorticoid receptor modulators/agonists）目标：提高治疗指数——尽量保留关键疗效，同时减少部分不良反应疗效/副作用的分离不等同于旧观点“转录激活=副作用、转录抑制=疗效”的简单二分；更像是不同的基因调控谱/共调节因子招募谱/偏向性（biased）常见科研或应用场景场景（科研/应用）典型“在做什么事”常用读出/方法（科研端常见）关键注意点生理学/应激生物学（HPA axis）在应激/炎症/饥饿时：协调能量与免疫反应；通过负反馈把反应拉回稳态皮质醇/ACTH 动态；GR 核转位；转录组变化“稳态维护 + 应激峰值”是同一套系统；时序很重要炎症免疫基础研究通过 GR 重排炎症基因网络：压制过强炎症，促进“分辨/收敛”ChIP-seq/ATAC-seq；GRE 报告基因；与 NF-κB/AP-1 的互作/“tethering”机制不是简单“关免疫”，而是重塑网络；细胞类型依赖很强呼吸：哮喘/慢阻肺（ICS 为核心治疗之一）抑制气道炎症、改善症状与急性发作风险；研究重点之一是激素不敏感/抵抗气道细胞 GR/HDAC2；炎症因子谱；临床表型分层“激素抵抗”涉及多环节（GR 异构体、染色质、氧化应激等）风湿免疫/自身免疫（RA、SLE、血管炎等）快速压制炎症“高峰”，桥接到免疫调节/生物制剂起效炎症评分、CRP；剂量递减试验；靶器官评价获益与风险高度依赖剂量/疗程/给药途径（局部 vs 全身）皮肤科/眼科/耳鼻喉（外用、滴眼、鼻喷）在局部组织把炎症压下来，同时尽量减少全身暴露局部症状量表；皮肤屏障/角膜指标“局部强效 + 低全身暴露”是很多场景常用逻辑（但仍需警惕长期使用）移植/过敏与免疫抑制方案抑制排斥/过敏级联，作为方案组件之一免疫细胞谱；排斥指标；感染监测免疫抑制与感染风险的平衡，是长期使用的核心矛盾肿瘤学与血液科（“辅助用药 + 某些肿瘤的 GR 生物学”）方案支持（止吐/抗过敏/减炎/减水肿等）；同时 GR 在某些肿瘤细胞命运与耐药中也被研究细胞凋亡/转录组；与化疗/免疫治疗联用研究同一通路在不同肿瘤可能“利弊不同”，需要分癌种/分情境解释内分泌：库欣综合征（高皮质醇）与药物对抗用 GR 拮抗/调节降低“过量皮质醇效应”带来的高血压/高血糖等临床终点（血压/糖代谢/症状）；安全性监测代表方向：选择性 GR 调节剂（如 relacorilant 的临床研究）神经精神/压力相关疾病研究研究 GR 过度激活与应激相关表型；探索更“精准”干预动物应激模型；脑区特异多组学；GR 相关基因调控新工具方向：GR 降解剂（PROTAC）等用于“关掉过强 GR”药物研发：提高治疗指数目标是“保留抗炎等获益、减少代谢/骨等副作用”共调节因子招募谱；组织选择性；长期安全性模型共识：不再等同于旧的“转录激活=副作用/转录抑制=疗效”二分法，机制更复杂“解耦副作用”的代表案例“解耦”或“选择性”类固醇/调节剂的临床落地临床获益 vs 骨/糖代谢不良反应例：vamorolone（Agamree）作为“选择性/解耦”类固醇的代表，已获 FDA 批准（DMD）缩写备注：1.HPA axis = hypothalamic–pituitary–adrenal axis（下丘脑–垂体–肾上腺轴）；2.GRE = glucocorticoid response element（糖皮质激素反应元件）；3.NF-κB = nuclear factor kappa B；4.AP-1 = activator protein-1；5.SEGRMs/SEGRAs = selective GR modulators/agonists（选择性 GR 调节剂/激动剂）；6.PROTAC = proteolysis-targeting chimera（靶向蛋白降解嵌合体）。最新研究进展层面方向性结论代表性要点/例子意义机制层面GR 不再被看作“简单进核开关”结构与生物物理新图景：解析 GR 构象、域间通讯与伴侣蛋白（Hsp90/Hsp70 等）如何协同调控 GR 成熟/活化，解释“同样配体为何转录谱不同”把“为什么同药不同效/不同副作用”从现象推进到机制：差异可能来自构象与复合体动态经典问题仍在演进：单体/二聚体/高阶状态多聚化/构象状态被刷新：2025 研究讨论 GR 多聚化构象与功能关系，提示“单体/二聚体/更高阶形式”的旧问题仍在更新影响如何解释“转录调控方式/剂量效应/细胞类型差异”的来源“异构体→个体差异”证据链更系统化GRα/GRβ 及更多异构体（剪接、翻译起始位点等）被更系统梳理，可解释组织特异性与个体差异/抵抗给“个体差异/激素抵抗”一个更可引用、可落地的机制框架药物层面从“激动剂/拮抗剂”走向“选择性调节 + 新型工具”选择性/解耦类固醇临床落地：vamorolone 获 FDA 批准用于 DMD，被视为提高获益/风险的重要里程碑证明“选择性/解耦”不只是概念，开始出现真实世界落地样例新型 SEGRM/SGRM 持续出现（但多在早期）GRM-01（2025）：动物模型提示“抗炎效应与糖/骨代谢不良反应分离”的探索方向（仍偏早期/一期）传达出方向在推进，但仍需谨慎表述证据等级（早期/动物）库欣综合征方向：临床证据持续积累relacorilant：含 Phase 3 与延伸研究，III 期（GRACE/GRADIENT）与长期延伸研究已给出改善高血压/糖代谢等临床终点的证据；监管审批仍以官方最终结论为准。代表“阻断/调节过强皮质醇效应”的现实临床路径仍在加固“不是拮抗而是降解”的新路线GR PROTAC 降解剂（Nature Communications 2023）：作为研究工具/潜在治疗概念，代表新工具链扩展工具箱：从“调节活性”到“直接移除受体”疾病层面激素抵抗与精准分层更受重视严重哮喘激素不敏感/抵抗仍是核心难题；综述强调需个体化分层并总结多层级机制把“为什么有人无效”从单一靶点问题升级为“分层+多环节网络”问题遗传变异与表型关联持续出现NR3C1 变异与哮喘严重度/控制等关联研究持续出现（效应依赖队列与表型定义）提醒：可用来解释差异，但需要避免过度外推主要瓶颈瓶颈本质原因（为什么难）对研发/临床/科研意味着什么疗效与副作用难以彻底解耦旧二分法（转录激活=副作用/转录抑制=疗效）被削弱；更像在不同细胞/染色质/共调节因子背景下，GR 选择性重排网络设计“对所有人都完美”的 SEGRM 很难；同一分子在不同组织可能出现不同收益/风险个体差异 & 用药前预测指标不足受 GR 异构体比例、伴侣蛋白/共调节因子、局部代谢、表观遗传等多因素影响，但缺少稳定、可推广的预测体系现实上难以在用药前精准预测谁更有效/谁更易副作用；试错成本高激素抵抗（glucocorticoid resistance/insensitivity）长期痛点在严重哮喘/慢性气道炎症等，抵抗涉及氧化应激、染色质调控（如 HDAC2 链条）、GR 信号多环节失衡，单点修复往往不够需要“分层 + 组合干预/多靶点”思路；单一机制解释经常不够非基因组（non-genomic）快速效应统一框架不够稳快速效应（秒–分钟）被确认，但受体定位、膜相关机制、不同组织贡献比例复杂“如何利用/规避快速效应”尚难工程化；不同模型结论可能不一致糖皮质激素 & 受体相关代表产品选型表（GR/MR 工具化合物 × 系统/基准与可溶性形式 × 局部制剂/缓释）先定在做什么，再选表：1、要验证 GR/MR 通路、做拮抗/激动对照或机制拆分 → 看表1（受体工具）2、要做定量/质控、建立“系统用基准对照”，或需要水溶/注射形式便于加样/给药 → 看表2（系统与基准）3、目标是局部治疗/局部模型（气道、鼻腔、眼表、皮肤）或关注“局部滞留/前药/缓释/制剂形态” → 看表3（局部与制剂）表1｜受体工具化合物：GR/MR 调节、拮抗与探针（机制验证/通路拆分）分类Cas编号阿拉丁货号名称规格或纯度产品应用或特色糖皮质激素受体相关｜GR 调节/拮抗剂1496510-51-0R669597RelacorilantMoligand™, ≥98%选择性 GR 调节/拮抗方向小分子；用于 GR 通路阻断、耐药/代谢效应研究与对照。糖皮质激素受体相关｜GR 拮抗剂2222344-98-9O648769ORIC-101≥99%GR 拮抗剂方向小分子；常用于 GR 阻断、联用机制与“抗糖皮质激素”药理研究对照。糖皮质激素受体相关｜选择性 GR 调节剂1018679-79-2C171679CORT-108297≥97%选择性 GR 调节剂方向工具化合物；用于区分不同 GR 下游通路（转录激活/抑制等）机制研究。糖皮质激素受体相关｜高亲和 GR 激动剂（研究探针）1110-40-3C667938Cortivazol_超高亲和力 GR 激动剂探针；用于受体结合/占有率、信号放大与机制验证实验。糖皮质激素受体相关｜GR 调节/拮抗剂1496508-34-9D649407Dazucorilant_GR 调节/拮抗方向小分子；用于“抗糖皮质激素效应”、应激/代谢相关药理与机制对照。糖皮质激素受体相关｜GR（兼 PR）拮抗剂84371-65-3M126999米非司酮Moligand™, ≥98%常用 GR 阻断对照（亦具 PR 拮抗活性）；用于应激轴/代谢与“抗糖皮质激素效应”机制研究。糖皮质激素受体相关｜选择性 GR 激动剂（研究探针）74915-64-3R613329RU28362Moligand™研究级选择性 GR 激动剂工具化合物；用于受体信号通路、选择性与机制拆分实验。矿皮质激素受体相关｜GC 合成前体/代谢通路对照152-58-9C302974脱氧可的松Moligand™, ≥98%矿皮质激素样（偏 MR 激动）对照；用于盐皮质激素/电解质稳态模型与受体选择性研究。矿皮质激素受体相关｜MR 激动剂64-85-7D13397211-去氧皮质酮Moligand™, ≥97%(HPLC)MR 激动方向的经典类固醇对照；常用于区分 GR vs MR 相关效应与受体通路比较。矿皮质激素样｜MR 激动剂（兼 GC）514-36-3F420036醋酸氟氢可的松≥98%矿皮质激素样代表（MR 活性突出，兼具一定 GC 活性）；用于受体选择性与电解质稳态相关研究对照。表2｜系统/基准用糖皮质激素 + 标准品 + 水溶/注射可用形式分类Cas编号阿拉丁货号名称规格或纯度产品应用或特色分析标准品/标准品｜糖皮质激素52-21-1P129282醋酸泼尼松龙分析标准品常用于 LC/LC-MS 定量校准、方法学开发与质控；亦可作局部制剂/眼科用激素对照品。分析标准品/标准溶液｜糖皮质激素83-43-2M121766甲基泼尼松龙标准溶液Moligand™, 分析标准品, 100 ng/ul in Acetonitrile预配标准溶液（乙腈中），便于直接用于 LC/LC-MS 建曲线与回收率/基质效应评估。分析标准品/标准溶液｜糖皮质激素378-44-9B121764甲醇中倍他米松溶液标准物质Moligand™, 分析标准品, 1.00mg/ml预配标准溶液（甲醇中），适合快速用于定量、方法确认与批间一致性对照。分析标准品｜内源性糖皮质激素（皮质酮）50-22-6C119329皮质甾酮Moligand™, 分析标准品啮齿类常见主导 GC（HPA 轴/应激研究常用）；用于定量检测与内分泌模型对照。内源性糖皮质激素｜细胞培养级50-23-7H657409氢化可的松Moligand™, 无动物源, 低内毒素, 用于细胞培养, ≥98%内源性“皮质醇”对照；无动物源/低内毒素，更适合细胞培养补充 GC 信号或受体激活实验。内源性糖皮质激素｜代谢/酶学对照53-06-5C119445可的松Moligand™, ≥97%需经 11β-HSD 转化为活性皮质醇；常用于代谢/酶学、内分泌与受体研究对照。酯化前体｜糖皮质激素50-04-4C129280醋酸可的松≥98%(HPLC)可的松乙酸酯（前体/酯化形式）；用于代谢/受体比较与制剂对照。系统用｜糖皮质激素53-03-2P116562强的松Moligand™, ≥98%经典系统用 GC 前体；用于体内抗炎/免疫模型与不同类固醇横向比较。系统用/对照｜糖皮质激素50-24-8P276607泼尼松龙≥98%经典系统用 GC；常作体内药效学对照、与其盐/酯之间溶解性与效应差异比较。系统用｜糖皮质激素14484-47-0D129585地夫可特Moligand™, ≥98%(HPLC)系统用激素代表；用于体内抗炎/免疫抑制相关模型与不同 GC 的效力比较研究。API/GMP 原料｜糖皮质激素50-02-2D137736地塞米松≥98%适合制剂开发、工艺/质量研究相关实验用对照。水溶性盐/溶液｜糖皮质激素（磷酸盐）125-02-0P1499394泼尼松龙磷酸二钠Moligand™, 10 mM in Water水溶性磷酸盐溶液，便于水相体系（细胞/体外）直接加样；也常作注射/水溶性形式对照。水溶性盐/注射前体｜糖皮质激素（磷酸盐）2392-39-4D107196地塞米松磷酸钠Moligand™, ≥98%高水溶性磷酸钠盐；适合水相细胞实验与动物给药，常作 GR 激动/抗炎强效对照。水溶性盐/注射前体｜糖皮质激素（半琥珀酸盐）2375-03-3M1688956α-甲基泼尼松龙21-半琥珀酸钠盐≥98%水溶性半琥珀酸钠盐（注射常见形式）；便于水相配制与体内给药/快速起效对照。水溶性盐/注射前体｜糖皮质激素（琥珀酸盐）125-04-2H329245氢化可的松琥珀酸钠≥98%高水溶性琥珀酸钠盐；适合水相体系与动物快速给药，对照“快速可用的注射形式”。注射前体（琥珀酸酯）｜糖皮质激素2203-97-6H132728氢化可的松琥珀酸酯≥95%琥珀酸酯提高水溶性（常与钠盐配套思路）；用于注射/水相配制与体内给药对照。糖皮质激素母体｜研究/对照124-94-7T129207曲安西龙Moligand™, ≥99%曲安西龙母体（非缩酮）；用于 GC 抗炎对照、结构-活性比较或衍生物/制剂研究。表3｜局部制剂为主（吸入/鼻用/眼科/皮肤外用）+ 缓释注射/制剂前体分类Cas编号阿拉丁货号名称规格或纯度产品应用或特色局部注射缓释/外用｜中效糖皮质激素76-25-5T101294曲安缩松Moligand™, ≥99%曲安奈德缩酮类代表；常用于外用或局部注射缓释相关研究，对照“较长作用/较强局部效应”。局部注射缓释｜糖皮质激素（长效）5611-51-8T346633己曲安奈德≥98%典型长效缓释（关节腔/局部注射）代表；用于慢释放动力学、关节炎/局部炎症模型对照。吸入/鼻用｜糖皮质激素5534-09-8B129370二丙酸倍氯米松Moligand™, ≥98%(HPLC)经典吸入/鼻用激素代表；二丙酸酯提高脂溶性与局部作用，适合呼吸道局部抗炎对照。吸入/鼻用｜前药型糖皮质激素126544-47-6C287438环索奈德Moligand™, ≥98%(HPLC)吸入/鼻用前药型（局部活化）代表；适合研究“局部作用/降低系统暴露”的机制与制剂策略。吸入/鼻用（亦可肠道局部）｜糖皮质激素51333-22-3B129941布地奈德Moligand™, ≥98%经典吸入/鼻用激素；也常作为局部抗炎对照用于气道/肠道相关模型与制剂研究。吸入/鼻用｜糖皮质激素80474-14-2F129894丙酸氟替卡松Moligand™, ≥97%经典吸入/鼻用激素对照；适合气道局部抗炎模型、制剂与稳定性研究。吸入/鼻用｜糖皮质激素（长效）397864-44-7F413479糠酸氟替卡松Moligand™, ≥98%高效长效吸入/鼻用激素代表；适合呼吸道局部作用、受体效力与滞留特性比较研究。外用/鼻用｜强效糖皮质激素83919-23-7M157957糠酸莫米他松≥98%(HPLC)强效局部激素代表（皮肤外用/鼻用常见）；适合高效局部抗炎对照与配方研究。眼科局部｜糖皮质激素（软甾体）82034-46-6L129196依碳酸氯替泼诺Moligand™, ≥98%(HPLC)眼科“软甾体”代表（易代谢失活的设计思路）；适合滴眼剂/眼表炎症模型与配方研究。眼科局部｜糖皮质激素426-13-1F138831氟米龙Moligand™, ≥98%(HPLC)常见眼科用激素对照；适合眼部局部抗炎、滴眼制剂筛选与稳定性研究。眼科局部｜强效糖皮质激素23674-86-4D129472二氟孕甾丁酯Moligand™, ≥98%眼科强效含氟激素代表；适合滴眼制剂/眼内或眼表炎症模型对照与方法学研究。眼科局部｜糖皮质激素49697-38-3R337073利美索龙Moligand™眼科用激素代表；适用于滴眼制剂筛选、眼表/前节炎症模型与对照实验。皮肤外用｜低～中效糖皮质激素638-94-8D129996地索奈德Moligand™, ≥99%低～中效外用激素对照；适合皮肤炎症模型、配方与渗透/滞留筛选。皮肤外用｜中效糖皮质激素（酯）57524-89-7H336850氢化可的松17-戊酸酯≥99%17-戊酸酯提高脂溶性与皮肤滞留；适合外用配方、透皮与局部药效对照。皮肤外用｜中效糖皮质激素（酯）13609-67-1H15736917-丁酸氢化可的松酯≥98%(HPLC)丁酸酯外用代表；用于外用制剂筛选、皮肤局部抗炎对照与渗透评价。皮肤外用｜前药型糖皮质激素74050-20-7H648363Hydrocortisone aceponate_外用前药型设计（局部活化/滞留）；常用于皮肤炎症模型、配方与透皮评价。皮肤外用｜中效糖皮质激素（酯）66734-13-2A354948丙酸氯米松_外用酯化激素代表；适合皮肤局部抗炎对照与制剂筛选。皮肤外用｜中效糖皮质激素25122-57-0C303211丁酸氯倍他松≥98%中效外用激素代表；适合皮肤局部抗炎对照、配方与刺激性/耐受性比较研究。皮肤外用｜前药型糖皮质激素73771-04-7P348401泼尼甲酸盐Moligand™, ≥99%外用前药型设计（局部活化/降低全身暴露倾向）；常用于皮肤制剂与药效学对照。皮肤外用｜中～强效糖皮质激素2152-44-5B123298倍他米松 17-戊酸酯≥98%戊酸酯提高脂溶性与局部滞留；用于外用药效、渗透与配方筛选对照。皮肤外用｜中～强效糖皮质激素（新戊酸酯）2002-29-1F486837新戊酸氟米松_新戊酸酯提高脂溶性与局部滞留；用于外用配方、渗透/滞留与药效对照研究。皮肤/黏膜局部｜糖皮质激素152-97-6F337919氟可龙≥96%局部用 GC 代表；适合皮肤/黏膜局部抗炎对照与相关制剂研究。皮肤外用｜强效糖皮质激素356-12-7F129893氟轻松Moligand™, ≥98%(HPLC)强效外用激素代表；用于皮肤炎症模型、透皮/滞留评价与配方优化。皮肤外用｜强效糖皮质激素（含氟）67-73-2F129244醋酸肤轻松Moligand™, ≥98%典型强效外用糖皮质激素对照；常用于皮肤炎症/免疫反应模型、外用制剂筛选与“局部滞留/透皮”比较研究。皮肤外用｜强效糖皮质激素382-67-2D336852去羟米松Moligand™, ≥98%强效外用激素代表；常用于皮肤抗炎对照、红斑/水肿等药效学模型与配方筛选。皮肤外用｜强效糖皮质激素33564-31-7D337813双醋酸双氟松Moligand™, ≥98%强效外用“二醋酸酯”代表；用于提高脂溶性/皮肤滞留的配方策略与药效对照。皮肤外用｜强效糖皮质激素59198-70-8D304084双氟可龙戊酸酯≥98%强效外用“戊酸酯”代表；用于局部抗炎对照、配方与皮肤滞留/渗透研究。皮肤外用｜强效糖皮质激素（双酯）5593-20-4B12329717,21-二丙酸倍他米松酯≥97%双酯提高脂溶性与皮肤滞留；用于强效外用对照、配方与渗透/滞留评价。皮肤外用｜超强效糖皮质激素25122-46-7C123300丙酸氯倍他索Moligand™, ≥98%超强效外用激素代表；用于强抑炎对照、受体高激动效应研究或高门槛皮肤模型。皮肤外用｜超强效糖皮质激素66852-54-8H129467卤贝他索丙酸酯≥98%超强效外用激素代表；用于强抑炎对照、难治皮肤模型与受体效力上限对照。酯化/脂溶性制剂前体｜糖皮质激素1177-87-3D773875乙酸地塞米松Moligand™, ≥96%脂溶性乙酸酯；适合有机溶剂配制、局部制剂/缓释或眼科对照研究。酯化/局部制剂｜糖皮质激素50-03-3H102192醋酸氢化可的松≥98%乙酸酯常用于外用/局部制剂对照；适合配方筛选、稳定性与局部药效研究。酯化/制剂前体｜糖皮质激素53-36-1M3361976α-甲基泼尼松龙21-乙酸盐≥98%甲基泼尼松龙乙酸酯类；常用于制剂/缓释策略、结构-活性比较与对照实验。阿拉丁：

2025-11-05

·中华风湿

ACR2025 速递 | 187名患儿研究证实：启动TNFi时，加用关节内激素注射未能提升长期缓解率

↑↑↑ 点击上方蓝色字关注“中华风湿” 孩子得了关节炎，家长最关心的就是怎么治疗最有效、最稳妥。近年来，生物制剂如TNF-α抑制剂（如融合蛋白TNFi等）已成为治疗 Juvenile Idiopathic Arthritis, JIA（幼年特发性关节炎）的重要武器。然而，即便用了这些“王牌药”，仍有近六成患儿病情控制不理想。于是，很多医生会在用药基础上，为发炎的关节“额外打一针”——注射一种叫做“曲安奈德己酸酯”的长效激素，希望能更快控制局部炎症。这种做法听起来很合理，但到底有没有用？一直缺乏严谨的研究证实。最近，一项名为 MyJIA 的多中心临床研究结果正式公布，回答了这个问题。研究是怎样进行的? 这项研究是一项高质量的随机对照试验，共纳入了187名非全身型的JIA患儿，年龄在1–18岁之间，所有孩子都在开始使用TNi治疗。他们被随机分成两组：注射组（92人）：除了用药，还对发炎的关节进行激素注射；非注射组（95人）：仅使用融合蛋白TNFi，不进行关节注射。研究人员对评估病情的医生隐瞒了分组信息，确保结果评价客观公正。研究的主要目标是看两组患儿在治疗24周和36周时，是否达到“疾病不活动”的状态。表1.基线人口统计学资料与疾病特征结果出乎意料：长期效果无差异经过48周的随访，研究得到了非常明确的结果：在主要目标上注射组达到“持续疾病不活动”的比例是35%，非注射组是33%，两组几乎没有差异。也就是说，额外打针并没有让孩子长期不发病的机会变得更高。在短期缓解上打针确实在早期（6–24周）显示出优势，例如在6周时，注射组达到ACR30缓解标准的比例高出12%，但这种优势随时间逐渐减弱，到48周时已基本消失。在安全性上两组发生不良反应的比例接近，注射组有8例（占所有注射关节的3%）出现注射部位皮下萎缩，其他严重不良事件无明显增加。图1.评估关节内注射曲安奈德己酸酯在起始TNFi治疗的JIA患者中的疗效专家怎么看？对我们有什么启示？这项研究告诉我们一个关键信息：对于正要开始使用TNFi的JIA患儿来说，常规加用关节内激素注射并不能进一步提升长期疗效。也就是说，在启动生物制剂治疗时，“多打一针”并不能让孩子更长久地保持病情不活动。当然，这并不否定关节注射在某些特定情况下的价值——比如某个关节肿痛非常突出，需要快速缓解症状时，局部注射仍然是一个有用的“救火队员”。给家长的温馨提示如果孩子正在接受规范的JIA治疗，不必过度追求“多加一针”。 TNFi是现代治疗的核心，其效果已经得到广泛验证。任何治疗调整都应在风湿科医生指导下进行，不盲目跟风，也不随意停换药。总之，医学的进步，正是靠这样一项项严谨的临床试验，不断优化治疗策略，让孩子在疗效与安全之间找到最佳平衡。MyJIA研究正是这样一步重要的探索——它告诉我们：有时候，少即是多。参考文献 [1].Büyesen P, Aga A, Lilleby V, Pesonen M, Rygg M, Nordal E, Barstad B, Tylleskär K, Sanner H, Hetlevik S, Sande N, Olsen I, Lillegraven S, Haavardsholm E, Ramanan A, Molberg O, Flatø B. Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/long-term-efficacy-of-intra-articular-triamcinolone-hexacetonide-injections-in-juvenile-idiopathic-arthritis-patients-starting-tumor-necrosis-factor-inhibitor-therapy-48-weeks-results-from-a-randomiz/. Accessed November 5, 2025. ↑↑↑ 点击关注“中华风湿”与大家共成长版权声明：本站所有注明“来源：中华风湿”的文字、图片和音视频资料，版权均属于中华风湿所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：中华风湿微信公众号”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。

临床结果引进/卖出ASCO会议

2021-06-09

·BioSpace

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the United States via the U.S. Food and Drug Administration’s (FDA) CDER Drug Shortage program. More information about the FDA’s Drug Shortage program is available at: FDA Drug Shortages. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. To address the ongoing shortage of TH in the United States, Medexus is coordinating with Ethypharm, its licensing partner, to generate the data needed to support an Abbreviated New Drug Application (ANDA) filing in an expedited timeframe. About Medexus Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive Officer Medexus Pharmaceuticals Inc. Tel.: 905-676-0003 E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial Officer Medexus Pharmaceuticals Inc. Tel.: 514-344-8765 E-mail: roland.boivin@medexus.com Investor Relations (U.S.): Crescendo Communications, LLC Tel: +1-212-671-1020 Email: mdp@crescendo-ir.com Investor Relations (Canada): Tina Byers Adelaide Capital Tel: 905-330-3275 E-mail: tina@adcap.ca Forward looking and other cautionary statements Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). The words “anticipates”, “believes”, “expects”, “will”, “plans” and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this news release include, but are not limited to, statements with respect to the immediate availability of TH in the United States and the Company’s ability to generate the data needed to support an ANDA filing in an expedited timeframe. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including the Company’s most recent annual information form and management’s discussion and analysis. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Best in Class

100 项与己曲安奈德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00985	己曲安奈德	R01AD11 H02AB08 S01BA05	DBSALT000861

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
类风湿关节炎	加拿大	Medexus, Inc.	2017-12-12
斑秃	美国	Ethypharm SAS	1969-07-29
斑秃	美国	ETHYPHARM INC	1969-07-29
环形肉芽肿	美国	ETHYPHARM INC	1969-07-29
环形肉芽肿	美国	Ethypharm SAS	1969-07-29
瘢痕疙瘩	美国	Ethypharm SAS	1969-07-29
瘢痕疙瘩	美国	ETHYPHARM INC	1969-07-29
盘状红斑狼疮	美国	Ethypharm SAS	1969-07-29
盘状红斑狼疮	美国	ETHYPHARM INC	1969-07-29
类脂质渐进性坏死	美国	ETHYPHARM INC	1969-07-29
类脂质渐进性坏死	美国	Ethypharm SAS	1969-07-29
神经性皮炎	美国	Ethypharm SAS	1969-07-29
神经性皮炎	美国	ETHYPHARM INC	1969-07-29
斑块状银屑病	美国	Ethypharm SAS	1969-07-29
斑块状银屑病	美国	ETHYPHARM INC	1969-07-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2020	N/A	幼年特发性关节炎一线	102	Triamcinolone hexacetonide	壓積網糧鬱觸網膚淵製(構獵襯鑰壓鹽鹹獵遞襯) = 築壓簾醖窪範鬱餘選蓋憲獵積憲鏇鏇艱觸遞鹽 (窪廠遞衊鏇齋網積鏇網 ) 更多	积极	2020-11-07
				Triamcinolone acetonide	壓積網糧鬱觸網膚淵製(構獵襯鑰壓鹽鹹獵遞襯) = 簾遞鏇餘糧餘憲淵願窪憲獵積憲鏇鏇艱觸遞鹽 (窪廠遞衊鏇齋網積鏇網 ) 更多
NCT01770912 (CTgov)	临床2期	疼痛 \| 肌痛	24	Lactated Ringers (Lactated Ringers)	鏇鹽淵遞觸廠製範窪願(壓窪淵遞艱獵餘鬱鬱鹽) = 齋簾鏇憲鹽夢遞襯鏇壓淵獵顧壓壓夢築獵獵鏇 (鏇壓醖艱顧糧餘簾鏇鏇, 憲艱鬱窪製糧廠鑰夢膚 ~ 顧網製鏇構鹽艱襯餘膚) 更多	-	2020-10-08
				Triamcinolone hexacetonide (Triamcinolone Acetonide)	鏇鹽淵遞觸廠製範窪願(壓窪淵遞艱獵餘鬱鬱鹽) = 鹽淵醖醖範壓觸範顧壓淵獵顧壓壓夢築獵獵鏇 (鏇壓醖艱顧糧餘簾鏇鏇, 艱製糧積醖積膚衊鏇繭 ~ 願繭願鏇廠繭襯鹹願鏇) 更多
EUCTR2014-000993-20-SE \| NCT02437461 (Pubmed \| Scand J Rheumatol)	临床4期	膝关节滑膜炎 \| 多发性关节炎	159	20 mg THA	廠鏇鏇繭製膚遞築蓋壓(觸淵構構繭鑰窪餘鏇築) = 醖網簾獵鏇鏇鹽窪網觸膚憲廠獵網蓋構製鹽襯 (襯製顧醖選構艱壓顧襯 )	-	2019-07-01
				40 mg THA	廠鏇鏇繭製膚遞築蓋壓(觸淵構構繭鑰窪餘鏇築) = 齋築壓簾願鹹膚遞遞鏇膚憲廠獵網蓋構製鹽襯 (襯製顧醖選構艱壓顧襯 )
EULAR2018	N/A	膝关节滑膜炎	159	20 mg triamcinolone hexacetonide	鑰膚糧鹽糧膚衊蓋廠積(鑰網醖觸網蓋鏇選繭膚) = 餘餘艱醖鬱繭獵鹽憲製構鏇願繭鏇選選窪遞衊 (積範遞繭鹹窪繭憲鹽遞 )	-	2018-06-13
				40 mg triamcinolone hexacetonide	鑰膚糧鹽糧膚衊蓋廠積(鑰網醖觸網蓋鏇選繭膚) = 衊醖艱夢壓築蓋選鹽選構鏇願繭鏇選選窪遞衊 (積範遞繭鹹窪繭憲鹽遞 )
NEO-RACo trial (EULAR2015)	临床3期	类风湿关节炎	99	Intensified combination of methotrexate, sulfasalazine, hydroxychloroquine, low-dose prednisolone, and IACIs	鑰鹽構窪積顧膚醖淵網(鹹製膚選窪糧繭壓獵憲) = 顧齋餘簾鹹夢醖鹽夢簾淵製壓繭獵築遞蓋築獵 (餘淵積膚壓鹽窪構餘築 )	积极	2015-06-10
EULAR2014	N/A	风湿性疾病	-	Triamcinolone hexacetonide intra-articular injection	築糧艱鹽觸鬱構製鏇淵(獵簾蓋壓範糧鑰範憲觸) = 壓遞積鏇夢繭觸鹽廠遞獵夢鏇選製蓋願壓積鬱 (糧製願鹹餘簾夢餘構遞 )	-	2014-06-11